Drugs / RO7119929
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04338685 | Jul 2020 → Jan 2023 | biliary tract cancer, hepatocellular carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7119929 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04338685 ↗ |
| Action | Activate | “TLR7 agonist” NCT04338685 ↗ |
| Route | Oral | “RO7119929 will be administered orally as a capsule” NCT04338685 ↗ |
| Target | TLR7 | “TLR7 agonist” NCT04338685 ↗ |